Alfa Cytology's Hu-Immune™ Platform Accelerates Immunotherapy Drug Development with Human-Relevant Models

Alfa Cytology's Hu-Immune™ humanized mouse platform is transforming preclinical immunotherapy studies. Traditional models often fail to predict human immune responses, escalating R&D costs. This innovative platform provides experimental conditions closely mimicking the human body, enabling efficient evaluation of drug efficacy and immune mechanisms for tumor and autoimmune disease treatments.

The platform offers comprehensive huPBMC and huHSC humanized mouse model services, establishing a systematic research pipeline from discovery to in vivo validation. Researchers analyze drug targeting and immunomodulatory effects within a human-like immune environment, utilizing diverse tumor models. These services facilitate critical studies on tumor growth, immune microenvironment, and drug distribution, generating reliable data for optimizing strategies.

Alfa Cytology ensures experimental reproducibility and reliability via standardized procedures and cross-model validation, yielding consistent in vivo results. Providing a robust scientific basis for drug optimization, dose design, and combination therapy, it improves preclinical decision-making and accelerates development. These human-relevant experiments offer a solid foundation for preclinical translation.